Context Therapeutics (CNTX) Competitors $0.87 +0.01 (+0.82%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$0.86 0.00 (-0.53%) As of 05/2/2025 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTX vs. OLMA, TRDA, BNTC, RNAC, MBX, SEPN, GLUE, PROK, ATAI, and ATYRShould you be buying Context Therapeutics stock or one of its competitors? The main competitors of Context Therapeutics include Olema Pharmaceuticals (OLMA), Entrada Therapeutics (TRDA), Benitec Biopharma (BNTC), Cartesian Therapeutics (RNAC), MBX Biosciences (MBX), Septerna (SEPN), Monte Rosa Therapeutics (GLUE), ProKidney (PROK), Atai Life Sciences (ATAI), and Atyr PHARMA (ATYR). These companies are all part of the "pharmaceutical products" industry. Context Therapeutics vs. Olema Pharmaceuticals Entrada Therapeutics Benitec Biopharma Cartesian Therapeutics MBX Biosciences Septerna Monte Rosa Therapeutics ProKidney Atai Life Sciences Atyr PHARMA Olema Pharmaceuticals (NASDAQ:OLMA) and Context Therapeutics (NASDAQ:CNTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, community ranking, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability. Does the MarketBeat Community prefer OLMA or CNTX? Olema Pharmaceuticals received 10 more outperform votes than Context Therapeutics when rated by MarketBeat users. However, 79.41% of users gave Context Therapeutics an outperform vote while only 71.15% of users gave Olema Pharmaceuticals an outperform vote. CompanyUnderperformOutperformOlema PharmaceuticalsOutperform Votes3771.15% Underperform Votes1528.85% Context TherapeuticsOutperform Votes2779.41% Underperform Votes720.59% Does the media prefer OLMA or CNTX? In the previous week, Context Therapeutics had 11 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 16 mentions for Context Therapeutics and 5 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 0.82 beat Context Therapeutics' score of 0.80 indicating that Olema Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Context Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, OLMA or CNTX? Olema Pharmaceuticals has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500. Do insiders & institutionals have more ownership in OLMA or CNTX? 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 19.4% of Olema Pharmaceuticals shares are owned by company insiders. Comparatively, 3.0% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts recommend OLMA or CNTX? Olema Pharmaceuticals presently has a consensus price target of $27.67, indicating a potential upside of 392.29%. Context Therapeutics has a consensus price target of $6.17, indicating a potential upside of 609.14%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Context Therapeutics is more favorable than Olema Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Olema Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Context Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Is OLMA or CNTX more profitable? Olema Pharmaceuticals' return on equity of -53.56% beat Context Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Olema PharmaceuticalsN/A -53.56% -47.86% Context Therapeutics N/A -58.76%-55.80% Which has better valuation and earnings, OLMA or CNTX? Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOlema PharmaceuticalsN/AN/A-$96.65M-$2.21-2.54Context TherapeuticsN/AN/A-$23.96M-$0.49-1.77 SummaryContext Therapeutics beats Olema Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTX vs. The Competition Export to ExcelMetricContext TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$78.01M$6.85B$5.55B$8.03BDividend YieldN/A2.96%5.09%4.22%P/E Ratio-0.967.4722.7118.87Price / SalesN/A258.42405.55106.92Price / CashN/A65.8538.1834.62Price / Book1.186.566.794.34Net Income-$23.96M$143.41M$3.22B$248.06M7 Day Performance-7.49%3.35%3.36%3.19%1 Month Performance20.95%10.29%6.92%8.28%1 Year Performance-52.99%-3.67%16.17%5.03% Context Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTXContext Therapeutics2.2727 of 5 stars$0.87+0.8%$6.17+609.1%-50.3%$78.01MN/A-0.967Analyst ForecastAnalyst RevisionNews CoverageOLMAOlema Pharmaceuticals2.7056 of 5 stars$4.89-0.4%$27.67+465.8%-44.2%$334.15MN/A-2.2370Upcoming EarningsNews CoveragePositive NewsTRDAEntrada Therapeutics3.0017 of 5 stars$8.87+0.3%$25.67+189.4%-31.9%$333.47M$210.78M5.58110Upcoming EarningsNews CoveragePositive NewsBNTCBenitec Biopharma2.593 of 5 stars$13.64+0.4%$24.71+81.2%+69.7%$319.87M$80,000.00-9.0320Positive NewsRNACCartesian Therapeutics1.9816 of 5 stars$12.21+3.2%$42.67+249.4%-48.0%$316.32M$38.91M-0.2364Upcoming EarningsPositive NewsMBXMBX Biosciences2.6597 of 5 stars$9.35+2.0%$37.50+301.1%N/A$312.51MN/A0.0036SEPNSepterna2.3571 of 5 stars$7.00+8.4%$33.00+371.4%N/A$311.09M$1.08M0.00N/ANews CoveragePositive NewsGLUEMonte Rosa Therapeutics1.9598 of 5 stars$4.95-2.2%$15.50+213.1%-11.3%$304.47M$75.62M-2.7090Upcoming EarningsShort Interest ↑News CoveragePositive NewsPROKProKidney1.7319 of 5 stars$1.03+1.0%$5.00+385.4%-63.3%$301.48M$76,000.00-1.873Upcoming EarningsGap UpATAIAtai Life Sciences1.958 of 5 stars$1.46flat$10.50+619.2%-29.6%$291.70M$308,000.00-1.8080Gap UpATYRAtyr PHARMA2.7461 of 5 stars$3.27-2.4%$18.60+468.8%N/A$290.57M$235,000.00-3.4853Short Interest ↑Analyst RevisionNews CoverageGap Up Related Companies and Tools Related Companies OLMA Alternatives TRDA Alternatives BNTC Alternatives RNAC Alternatives MBX Alternatives SEPN Alternatives GLUE Alternatives PROK Alternatives ATAI Alternatives ATYR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTX) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CNTX Stock Free CNTX Stock Alerts